Shanghai ZJ Bio-Tech Yönetim

Yönetim kriter kontrolleri 2/4

Shanghai ZJ Bio-Tech CEO'su Junbin Shao, May2023 tarihinde atandı, in görev süresi 1.5 yıldır. şirketin hisselerinin 0.35% doğrudan sahiptir ve bu hisselerin değeri CN¥ 12.35M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 9.1 yıl ve 3.7 yıldır.

Anahtar bilgiler

Junbin Shao

İcra Kurulu Başkanı

CN¥1.3m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.5yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	9.1yrs
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

CEO

Junbin Shao (53 yo)

1.5yrs

Görev süresi

CN¥1,289,000

Tazminat

Mr. Junbin Shao serves as Chairman and Director at Shanghai ZJ Bio-Tech Co., Ltd. since August 2011 and serves as its General Manager since May 2023 and serves as its Dean of Research Institute & Director...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Junbin Shao	Chairman	1.5yrs	CN¥1.29m	0.35% CN¥ 12.4m
Weiqin Ni	Deputy GM	13.3yrs	CN¥1.05m	0.021% CN¥ 730.4k
Kai Wang	Deputy General Manager	4.8yrs	CN¥1.98m	Veri yok
Yiyun Wang	Deputy General Manager	1.8yrs	CN¥832.80k	Veri yok
Feng Shu	Synthesis Department Manager	9.1yrs	CN¥333.10k	Veri yok
Peixiao Li	Production Manager	9.1yrs	CN¥408.50k	Veri yok
Qinwei Zhu	Director of Product Development Center & Manager of Project Management Department	9.1yrs	CN¥509.60k	Veri yok
Jie Zhang	Core Technical Staff	9.1yrs	Veri yok	Veri yok
Yan Liu	Research Director	9.1yrs	Veri yok	Veri yok

9.1yrs

Ortalama Görev Süresi

43yo

Ortalama Yaş

Deneyimli Yönetim: 688317 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Junbin Shao	Chairman	13.3yrs	CN¥1.29m	0.35% CN¥ 12.4m
Weiqin Ni	Deputy GM	13.3yrs	CN¥1.05m	0.021% CN¥ 730.4k
Xueyao Li	Independent Director	4.5yrs	CN¥95.20k	Veri yok
Yongsheng Yu	Independent Director	4.5yrs	CN¥95.20k	Veri yok
Jingming Ma	Director	2.8yrs	CN¥163.30k	Veri yok
Haiyang Lin	Chairman of the Supervisory Board	1.5yrs	Veri yok	Veri yok
Xuerui Liu	Employee Representative Supervisor	1.5yrs	Veri yok	Veri yok
Ai Wang	Employee Representative Supervisor	1.8yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 688317 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

Shanghai ZJ Bio-Tech Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.21 loss per share (vs CN¥0.015 profit in 3Q 2023)

Shanghai ZJ Bio-Tech Co., Ltd to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.005 loss per share (vs CN¥0.15 profit in 2Q 2023)

Shanghai ZJ Bio-Tech Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: CN¥0.71 loss per share (vs CN¥3.93 profit in FY 2022)

Shanghai ZJ Bio-Tech Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Full year 2023 earnings released: CN¥0.67 loss per share (vs CN¥3.93 profit in FY 2022)

Shanghai ZJ Bio-Tech Co., Ltd. (SHSE:688317) announces an Equity Buyback for CNY 70 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 27% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: CN¥0.015 (vs CN¥0.81 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥1.04 in 2Q 2022)

Shanghai ZJ Bio-Tech Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings released: EPS: CN¥3.93 (vs CN¥3.98 in FY 2021)

Full year 2022 earnings released: EPS: CN¥3.82 (vs CN¥3.98 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥1.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.04 (vs CN¥0.36 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥3.98 (vs CN¥6.38 in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals appearing at China International Import Expo

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥2.27 in 2Q 2020)

Investor sentiment improved over the past week

CJ Cheiljedang Corporation (KOSE:A097950) signed a stock purchase contract to acquire 15.99% stake in ChunLab, Inc. (KOSDAQ:A311690) from Jong-sik Cheon and Shanghai ZJ Bio-Tech Co., Ltd. (SHSE:688317) for KRW 25 billion.

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥6.38 (vs CN¥0.35 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Shanghai ZJ Bio-Tech Co., Ltd. to Report Fiscal Year 2020 Results on Apr 22, 2021

Shanghai ZJ Bio-Tech Co., Ltd. has completed an IPO in the amount of CNY 2.103781 billion.

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş